Beecham Group Plc

Beecham-wuelfing Gmbh & Co. Kg

Brian Morgan

Keith H Baggaley

David Edward Thorne

Richard M Hindley

Joachim E Goring

Jonathan R Arch

Joseph Green

Dieter Angersbach

Charles D Nicholson

A method for the treatment of cerebral vascular and neuronal degenerative disorders associated with learning, memory and cognitive dysfunctions including cerebral senility, multi-infarct dementia and senile dementia of the Alzheimer type and/or peripheral vascular disease and/or proliferative skin disease in mammals, such as humans, which comprises administering to the mammal in need of such treatment an effective amount of 1,3-di-n-butyl-7-(2-oxypropyl) xanthine or a pharmaceutically acceptable salt thereof.

Novel treatment

A method for the treatment and/or prophylaxis of cerebrovascular disorders and/or disorders associated with cerebral senility in mammals, such as humans, which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective and/or prophylactic amount of a compound of formula (I): ##STR1## wherein (i) R.sub.1 is a group --X--CO--CH.sub.3 where X is a hydrocarbon radical having up to 4 carbon atoms which may be substituted by a methyl group,

Treatment of cerebrovascular disorders and/or disorders associated with

A class of di-(substituted phenoxy) alkanes having from 7 to 25 carbon atoms in the alkane moiety have hypolipidaemic activity.

Certain di-(substituted phenoxy) alkanes and hypolipidaemic use thereof

Pharmaceutical compositions having hypolipidaemic and/or hypoglycaemic activity, contain a substituted (4-carboxyphenoxy) phenyl alkane derivative.

Polycyclic oxy-aromatic acid

Substituted (4-carboxyphenoxy) phenyl alkane compounds

Phenyl alkyleneoxy phenyl alkanoic acid esters

Certain non-ionic surfactants have been found to be useful in reducing serum cholesterol levels in animals and man. The surfactants are incorporated to at least 20 percent in pharmaceutical compositions so that the (C.sub.2 H.sub.4 O) groups amount to 0 to 30 percent of total molecular weight and the (C.sub.3 H.sub.6 O) groups have a partial molecular weight of 2250 to 3250. The surfactants are prepared by sequential addition of ethylene diamine. 'Tetronic 701' and 'Tetronic 702' are suitable; others of the same series are not.

Growing community of inventors

Reigate, United Kingdom

Brian Morgan